Trial Profile
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ± ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms NICE Trial
- 13 Dec 2022 Preliminary results (n=35) of cohort B part of the study, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 24 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2022 Planned number of patients changed from 61 to 78.